Details of the Drug Combination

General Information of Drug Combination (ID: DCZA04Q)

Drug Combination Name
Hydrocortisone Dopamine
Indication
Disease Entry Status REF
Infant, Newborn Phase 1 [1]
Component Drugs Hydrocortisone   DMGEMB7 Dopamine   DMPGUCF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Hydrocortisone
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Acute adrenal insufficiency N.A. Approved [2]
Addison disease 5A74.0 Approved [2]
Allergic rhinitis CA08.0 Approved [2]
Angioedema 4A00.15 Approved [2]
Aspiration pneumonitis N.A. Approved [2]
Autoimmune haemolytic anaemia 3A20 Approved [2]
Blepharoconjunctivitis N.A. Approved [2]
Bursitis N.A. Approved [2]
Cerebral edema 8D60.1 Approved [2]
Corneal abrasion NA06.4 Approved [2]
Corneal ulcer 9A76 Approved [2]
Crohn disease DD70 Approved [2]
Dermatitis herpetiformis EB44 Approved [2]
Diamond-Blackfan anemia N.A. Approved [2]
Disorder of orbital region N.A. Approved [2]
Erythema multiforme N.A. Approved [2]
Exanthem N.A. Approved [2]
Gingival disorder N.A. Approved [2]
Granuloma annulare N.A. Approved [2]
Inflammation 1A00-CA43.1 Approved [3]
Inflammatory bowel disease DD72 Approved [2]
Keratitis N.A. Approved [2]
Malignant otitis externa caused by Pseudomonas aeruginosa N.A. Approved [2]
Multiple sclerosis 8A40 Approved [2]
Mycosis fungoides 2B01 Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Proctitis DB33.Z Approved [2]
Psoriasis EA90 Approved [2]
Psoriatic arthritis FA21 Approved [2]
Rheumatic heart disease N.A. Approved [2]
Rosacea ED90.0 Approved [2]
Sarcoidosis 4B20.5 Approved [2]
Serum sickness N.A. Approved [2]
Severe asthma CA23 Approved [2]
Systemic lupus erythematosus 4A40.0 Approved [2]
Tinea corporis 1F28.Y Approved [2]
Tinea cruris 1F28.3 Approved [2]
Ulcerative colitis DD71 Approved [2]
Viral pneumonia N.A. Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Congenital adrenal hyperplasia 5A71.01 Phase 2 [5]
Acquired thrombocytopenia N.A. Investigative [2]
Asthma CA23 Investigative [2]
Beta-thalassemia major N.A. Investigative [2]
Classic Hodgkin lymphoma N.A. Investigative [2]
Iridocyclitis N.A. Investigative [2]
Phobic disorder N.A. Investigative [2]
Rheumatoid arthritis FA20 Investigative [2]
Synovitis N.A. Investigative [2]
Tinea pedis 1F28.2 Investigative [2]
Trichinellosis N.A. Investigative [2]
Uveitis 9A96.Z Investigative [2]
Hydrocortisone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [11]
------------------------------------------------------------------------------------
Hydrocortisone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
------------------------------------------------------------------------------------
Hydrocortisone Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [15]
Steroid 11-beta-hydroxylase (CYP11B1) DEPE0RD C11B1_HUMAN Metabolism [16]
Aldosterone synthase (CYP11B2) DE6TYUK C11B2_HUMAN Metabolism [16]
------------------------------------------------------------------------------------
Hydrocortisone Interacts with 108 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 11B1, mitochondrial (CYP11B1) OTKKL894 C11B1_HUMAN Increases Chemical Synthesis [17]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [18]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases Expression [19]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Secretion [20]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Secretion [21]
Glutathione S-transferase A1 (GSTA1) OTA7K5XA GSTA1_HUMAN Increases Expression [22]
Protein-glutamine gamma-glutamyltransferase K (TGM1) OTB8URRI TGM1_HUMAN Increases Expression [23]
GDH/6PGL endoplasmic bifunctional protein (H6PD) OTO7TNDD G6PE_HUMAN Increases Expression [24]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Increases Expression [24]
Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12) OTZKOTDB ADA12_HUMAN Decreases Expression [25]
Mitogen-activated protein kinase kinase kinase 7 (MAP3K7) OTUXEASC M3K7_HUMAN Decreases Expression [25]
Integrin alpha-10 (ITGA10) OTM0V5AO ITA10_HUMAN Increases Expression [25]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Expression [25]
Integrin alpha-5 (ITGA5) OT3RCI67 ITA5_HUMAN Increases Expression [25]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Increases Expression [25]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [25]
Adhesion G protein-coupled receptor E5 (ADGRE5) OTTSB84Q AGRE5_HUMAN Decreases Expression [25]
Metallothionein-1X (MT1X) OT9AKFVS MT1X_HUMAN Increases Expression [25]
Collagen alpha-1(VII) chain (COL7A1) OT3MIRZJ CO7A1_HUMAN Decreases Expression [25]
Forkhead box protein O1 (FOXO1) OTPJRB6D FOXO1_HUMAN Increases Expression [25]
Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5) OT404F9K FKBP5_HUMAN Increases Expression [25]
Nuclear receptor subfamily 6 group A member 1 (NR6A1) OTFZOOQ9 NR6A1_HUMAN Decreases Expression [25]
Protein prune homolog 2 (PRUNE2) OTGW2974 PRUN2_HUMAN Decreases Expression [25]
Adhesion G-protein coupled receptor G1 (ADGRG1) OTQBB8NT AGRG1_HUMAN Decreases Expression [25]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [26]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1) OTNAZVKB 3BHS1_HUMAN Affects Binding [27]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Decreases Expression [28]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Affects Expression [28]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Affects Expression [28]
Steroidogenic acute regulatory protein, mitochondrial (STAR) OTFEZ5AI STAR_HUMAN Decreases Expression [28]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Increases Expression [28]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Decreases Expression [28]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Decreases Expression [29]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Decreases Expression [29]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [29]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Decreases Expression [29]
Scavenger receptor class B member 1 (SCARB1) OTAE1UA1 SCRB1_HUMAN Decreases Expression [29]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Decreases Expression [30]
Basic helix-loop-helix ARNT-like protein 1 (BMAL1) OTMI12L2 BMAL1_HUMAN Decreases Expression [10]
Dihydroxyacetone phosphate acyltransferase (GNPAT) OTF6LWPO GNPAT_HUMAN Increases Expression [8]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [31]
Period circadian protein homolog 1 (PER1) OTVQF3WX PER1_HUMAN Increases Expression [10]
Trehalase (TREH) OTJE0NOY TREA_HUMAN Decreases Activity [32]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [30]
Rap guanine nucleotide exchange factor 3 (RAPGEF3) OTMOW4Z4 RPGF3_HUMAN Increases Expression [8]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Expression [33]
Antithrombin-III (SERPINC1) OTDFATG0 ANT3_HUMAN Increases Expression [34]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Increases Expression [35]
Somatotropin (GH1) OT92RTRD SOMA_HUMAN Increases Expression [36]
Pro-neuropeptide Y (NPY) OT4ICV3P NPY_HUMAN Affects Expression [37]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [35]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [10]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Decreases Expression [10]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [38]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Increases Expression [39]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Increases Expression [8]
Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) OT2NV3AN CP11A_HUMAN Decreases Expression [40]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [34]
Kallikrein-1 (KLK1) OTFGP3UR KLK1_HUMAN Increases Export [35]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Increases Expression [41]
Involucrin (IVL) OT4VPNGY INVO_HUMAN Decreases Expression [42]
Pulmonary surfactant-associated protein B (SFTPB) OTOHS07E PSPB_HUMAN Increases Expression [43]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [44]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [30]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [45]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Affects Activity [46]
Pulmonary surfactant-associated protein C (SFTPC) OTIZJD09 PSPC_HUMAN Increases Expression [43]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [9]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [45]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [45]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Decreases Expression [47]
Filaggrin (FLG) OTE9QDV6 FILA_HUMAN Decreases Expression [42]
Loricrin (LORICRIN) OTFRPVEO LORI_HUMAN Decreases Expression [42]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Expression [8]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Increases Expression [10]
Cadherin-5 (CDH5) OTVX0E1Q CADH5_HUMAN Increases Localization [8]
T-lymphocyte activation antigen CD80 (CD80) OTJBLUQE CD80_HUMAN Decreases Expression [48]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Localization [8]
Nuclear receptor ROR-alpha (RORA) OTGQT12P RORA_HUMAN Increases Expression [10]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Increases Expression [49]
Amiloride-sensitive sodium channel subunit alpha (SCNN1A) OTE2KVZV SCNNA_HUMAN Increases Expression [50]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [48]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [49]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Decreases Expression [49]
Amiloride-sensitive sodium channel subunit beta (SCNN1B) OT61QQTL SCNNB_HUMAN Increases Expression [50]
Amiloride-sensitive sodium channel subunit gamma (SCNN1G) OTSJYQVQ SCNNG_HUMAN Increases Expression [50]
ATP-citrate synthase (ACLY) OTRL9ZRP ACLY_HUMAN Increases Expression [49]
Ras-related protein Rap-1A (RAP1A) OT5RH6TI RAP1A_HUMAN Increases Expression [8]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Increases Localization [8]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Expression [49]
Histone deacetylase 1 (HDAC1) OTQDNOXZ HDAC1_HUMAN Increases Expression [40]
Splicing factor 1 (SF1) OTLEDM2S SF01_HUMAN Decreases Expression [40]
Cryptochrome-1 (CRY1) OTTGAJT0 CRY1_HUMAN Increases Expression [10]
Atypical chemokine receptor 1 (ACKR1) OT9M11LX ACKR1_HUMAN Increases Expression [8]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Increases Expression [8]
Patatin-like phospholipase domain-containing protein 2 (PNPLA2) OTR3ERMR PLPL2_HUMAN Decreases Expression [49]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Decreases Expression [49]
TSC22 domain family protein 3 (TSC22D3) OT03UM03 T22D3_HUMAN Increases Expression [8]
Corticoliberin (CRH) OT2MOC4T CRF_HUMAN Increases Abundance [51]
Oxytocin-neurophysin 1 (OXT) OT48M72Z NEU1_HUMAN Affects Abundance [52]
Aldo-keto reductase family 1 member D1 (AKR1D1) OTBDJ6RL AK1D1_HUMAN Increases Reduction [53]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Increases Secretion [54]
Insulin-like growth factor II (IGF2) OTJ4O6MW IGF2_HUMAN Increases Secretion [55]
Histone-binding protein RBBP7 (RBBP7) OTLB56HX RBBP7_HUMAN Affects Response To Substance [56]
Glycodelin (PAEP) OTQA0NV4 PAEP_HUMAN Increases Metabolism [57]
Pro-opiomelanocortin (POMC) OTV41F7T COLI_HUMAN Increases Abundance [58]
T-box transcription factor TBX19 (TBX19) OTXEMR2U TBX19_HUMAN Decreases Abundance [59]
Interferon beta (IFNB1) OTYQGUB5 IFNB_HUMAN Decreases Secretion [55]
------------------------------------------------------------------------------------
⏷ Show the Full List of 108 DOT(s)
Indication(s) of Dopamine
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [6]
Carcinoid syndrome 5B10 Approved [6]
Parkinson disease 8A00.0 Approved [7]
Parkinsonian disorder N.A. Approved [6]
Postencephalitic Parkinson disease N.A. Approved [6]
Hypotension BA20-BA21 Phase 1 [7]
Dopamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [63]
------------------------------------------------------------------------------------
Dopamine Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [64]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [65]
Vesicular amine transporter 2 (SLC18A2) DTT7VPB VMAT2_HUMAN Substrate [66]
Vesicular amine transporter 1 (SLC18A1) DTM953D VMAT1_HUMAN Substrate [66]
Synaptic vesicle glycoprotein 2C (SLC22B3) DT7A9GF SV2C_HUMAN Substrate [67]
Sodium-dependent dopamine transporter (SLC6A3) DT3BA8L SC6A3_HUMAN Substrate [68]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Dopamine Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [69]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [70]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [70]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [70]
Catechol O-methyltransferase (COMT) DEV3T4A COMT_HUMAN Metabolism [71]
Monoamine oxidase type B (MAO-B) DET2NXO AOFB_HUMAN Metabolism [72]
Sulfotransferase 1B1 (SULT1B1) DED5UR3 ST1B1_HUMAN Metabolism [73]
Dopamine dehydroxylase (dadH) DEL0D64 DADH_EGGLN Metabolism [74]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Dopamine Interacts with 76 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Abundance [75]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Decreases Amination [76]
Catechol O-methyltransferase (COMT) OTPWKTQG COMT_HUMAN Increases Methylation [77]
Sodium-dependent dopamine transporter (SLC6A3) OT39XG28 SC6A3_HUMAN Increases Activity [78]
Synaptic vesicular amine transporter (SLC18A2) OTUOMMM6 VMAT2_HUMAN Decreases Activity [79]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Increases ADR [80]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [81]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [81]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [81]
Glutathione S-transferase A1 (GSTA1) OTA7K5XA GSTA1_HUMAN Decreases Activity [82]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Decreases Activity [82]
Glutathione S-transferase Mu 1 (GSTM1) OTSBF2MO GSTM1_HUMAN Decreases Activity [82]
Methionine synthase (MTR) OTF2K2TA METH_HUMAN Increases Activity [83]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [84]
POTE ankyrin domain family member F (POTEF) OTV3WXYE POTEF_HUMAN Increases Expression [60]
Citrate synthase, mitochondrial (CS) OTYLYXMO CISY_HUMAN Increases Expression [60]
ATP synthase subunit d, mitochondrial (ATP5PD) OTAJDLE2 ATP5H_HUMAN Increases Expression [60]
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Increases Expression [60]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Increases Expression [60]
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) OTBPMIMW G3P_HUMAN Increases Expression [60]
ADP/ATP translocase 2 (SLC25A5) OT1XIBMN ADT2_HUMAN Increases Expression [60]
Cathepsin D (CTSD) OTQZ36F3 CATD_HUMAN Increases Expression [60]
Heat shock protein HSP 90-beta (HSP90AB1) OTR69EG7 HS90B_HUMAN Increases Expression [60]
Small ribosomal subunit protein uS2 (RPSA) OTJZHEGT RSSA_HUMAN Increases Expression [60]
POTE ankyrin domain family member I (POTEI) OTST4AVP POTEI_HUMAN Decreases Expression [60]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [60]
ADP/ATP translocase 3 (SLC25A6) OT9KAJP7 ADT3_HUMAN Increases Expression [60]
Annexin A3 (ANXA3) OTDD8OI7 ANXA3_HUMAN Increases Expression [60]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Increases Expression [60]
Endoplasmin (HSP90B1) OT02XLBR ENPL_HUMAN Increases Expression [60]
Histone H1.5 (H1-5) OTAN7RD9 H15_HUMAN Increases Expression [60]
Heat shock 70 kDa protein 6 (HSPA6) OTH4S7WB HSP76_HUMAN Increases Expression [60]
Nucleolin (NCL) OTBXPKMP NUCL_HUMAN Increases Expression [60]
Cofilin-1 (CFL1) OTT6D5MH COF1_HUMAN Increases Expression [60]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Increases Expression [60]
Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) OTLB2WEU PRDX3_HUMAN Increases Expression [60]
Protein disulfide-isomerase A3 (PDIA3) OTHPQ0Q3 PDIA3_HUMAN Decreases Expression [60]
Serine hydroxymethyltransferase, mitochondrial (SHMT2) OT5NCAZN GLYM_HUMAN Increases Expression [60]
Prohibitin 1 (PHB1) OTZNXYS2 PHB1_HUMAN Increases Expression [60]
Stress-70 protein, mitochondrial (HSPA9) OT4TMVS9 GRP75_HUMAN Increases Expression [60]
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Affects Expression [60]
Small ribosomal subunit protein RACK1 (RACK1) OTZBCQ1U RACK1_HUMAN Increases Expression [60]
Elongation factor 1-alpha 1 (EEF1A1) OT00THXS EF1A1_HUMAN Increases Expression [60]
Single-stranded DNA-binding protein, mitochondrial (SSBP1) OTH2PZWH SSBP_HUMAN Increases Expression [60]
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) OTPYQX3K C1QBP_HUMAN Increases Expression [60]
Beta-actin-like protein 2 (ACTBL2) OTD6B81U ACTBL_HUMAN Decreases Expression [60]
5'-3' exonuclease PLD3 (PLD3) OTL07SP2 PLD3_HUMAN Affects Expression [60]
Septin-9 (SEPTIN9) OT1VMRFQ SEPT9_HUMAN Decreases Expression [60]
RuvB-like 1 (RUVBL1) OTWV19L7 RUVB1_HUMAN Increases Expression [60]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Increases Expression [85]
Brain mitochondrial carrier protein 1 (SLC25A14) OT1ZQSKS UCP5_HUMAN Increases Expression [86]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Affects Binding [87]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Decreases Expression [88]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [89]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [90]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [90]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [91]
D(1A) dopamine receptor (DRD1) OTLZPBT7 DRD1_HUMAN Increases Activity [92]
Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PCMT1) OTGYVSGU PIMT_HUMAN Decreases Expression [93]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [81]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [81]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [81]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [81]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Decreases Expression [81]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Increases Expression [81]
Sulfotransferase 1A1 (SULT1A1) OT0K7JIE ST1A1_HUMAN Increases Metabolism [94]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Uptake [95]
Tyrosine 3-monooxygenase (TH) OT6ZORKP TY3H_HUMAN Increases Chemical Synthesis [96]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Decreases Amination [76]
Sulfotransferase 1A3 (SULT1A4) OTHJ8WWV ST1A3_HUMAN Increases Metabolism [94]
Alpha-synuclein (SNCA) OTPWC1MR SYUA_HUMAN Increases Response To Substance [97]
Neuron-specific vesicular protein calcyon (CALY) OTQ7EMPU CALY_HUMAN Decreases Secretion [98]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Increases Uptake [99]
Secretin (SCT) OTV3MLOO SECR_HUMAN Increases Metabolism [100]
Equilibrative nucleoside transporter 4 (SLC29A4) OTWTZXMX S29A4_HUMAN Increases Uptake [99]
GDP-mannose 4,6 dehydratase (GMDS) OTWV79YD GMDS_HUMAN Increases ADR [62]
------------------------------------------------------------------------------------
⏷ Show the Full List of 76 DOT(s)

References

1 ClinicalTrials.gov (NCT00874393) Early Blood Pressure Management in Extremely Premature Infants
2 Hydrocortisone FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2868).
4 Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Dopamine FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940).
8 Hydrocortisone enhances the barrier properties of HBMEC/ci, a brain microvascular endothelial cell line, through mesenchymal-to-endothelial transition-like effects. Fluids Barriers CNS. 2015 Mar 5;12:7. doi: 10.1186/s12987-015-0003-0. eCollection 2015.
9 Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line. Cancer Chemother Pharmacol. 2008 Mar;61(3):471-9. doi: 10.1007/s00280-007-0492-x. Epub 2007 Jun 5.
10 Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS One. 2011;6(9):e25612. doi: 10.1371/journal.pone.0025612. Epub 2011 Sep 28.
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12 Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
13 Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
14 CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
15 Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
16 Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
17 Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
18 Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
19 Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
20 Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. doi: 10.1016/j.taap.2012.03.008. Epub 2012 Mar 23.
21 Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
22 Overexpression of glutathione-S-transferase A1 in benign adrenocortical adenomas from patients with Cushing's syndrome. J Clin Endocrinol Metab. 2001 Apr;86(4):1653-9.
23 Keratinocyte differentiation marker suppression by arsenic: mediation by AP1 response elements and antagonism by tetradecanoylphorbol acetate. Toxicol Appl Pharmacol. 2001 Aug 1;174(3):302-11.
24 Testosterone stimulates adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in a depot-specific manner in children. J Clin Endocrinol Metab. 2010 Jul;95(7):3300-8.
25 Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
26 CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
27 Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
28 Glucocorticoid-activation system mediated glucocorticoid-insulin-like growth factor 1 (GC-IGF1) axis programming alteration of adrenal dysfunction induced by prenatal caffeine exposure. Toxicol Lett. 2019 Mar 1;302:7-17.
29 Glucocorticoid programming mechanism for hypercholesterolemia in prenatal ethanol-exposed adult offspring rats. Toxicol Appl Pharmacol. 2019 Jul 15;375:46-56.
30 Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology. 2006;213(3):266. doi: 10.1159/000095056.
31 Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
32 Effect of hydrocortisone on the maturation of human foetal kidney explants in serum-free organ culture. Biochem Cell Biol. 1989 Feb-Mar;67(2-3):121-7. doi: 10.1139/o89-019.
33 Acute effects of hydrocortisone on plasma nitrate/nitrite activity and forearm vasodilator responsiveness in normal human subjects. Clin Exp Pharmacol Physiol. 2005 Mar;32(3):162-6. doi: 10.1111/j.1440-1681.2005.04173.x.
34 Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med. 2003 Apr;31(4):1068-74. doi: 10.1097/01.CCM.0000059646.89546.98.
35 Experimental studies on cortisol-induced hypertension in humans. J Hum Hypertens. 1995 Jun;9(6):395-9.
36 Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Addict Behav. 2005 May;30(4):859-64. doi: 10.1016/j.addbeh.2004.08.019.
37 Neuropeptide Y in cortisol-induced hypertension in male volunteers. Clin Exp Pharmacol Physiol. 1994 May;21(5):435-8. doi: 10.1111/j.1440-1681.1994.tb02538.x.
38 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
39 Role of erythropoietin in cortisol-induced hypertension. J Hum Hypertens. 2000 Mar;14(3):195-8. doi: 10.1038/sj.jhh.1000959.
40 Intergenerational genetic programming mechanism and sex differences of the adrenal corticosterone synthesis dysfunction in offspring induced by prenatal ethanol exposure. Toxicol Lett. 2021 Oct 15;351:78-88. doi: 10.1016/j.toxlet.2021.08.007. Epub 2021 Aug 25.
41 A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002 May;143(5):1889-900. doi: 10.1210/endo.143.5.8778.
42 Deducing signaling pathways from parallel actions of arsenite and antimonite in human epidermal keratinocytes. Sci Rep. 2020 Feb 19;10(1):2890. doi: 10.1038/s41598-020-59577-0.
43 Regulation of messenger RNAs for the hydrophobic surfactant proteins in human lung. J Clin Invest. 1989 Apr;83(4):1191-7. doi: 10.1172/JCI114000.
44 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
45 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
46 Screening of some anti-androgenic endocrine disruptors using a recombinant cell-based in vitro bioassay. J Steroid Biochem Mol Biol. 2004 Feb;88(2):157-66. doi: 10.1016/j.jsbmb.2003.11.005.
47 Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J Biol Chem. 1992 Dec 15;267(35):24917-20.
48 Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004 Jul;114(1):137-43. doi: 10.1016/j.jaci.2004.03.021.
49 Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBP-SIRT1 pathway. Toxicology. 2019 Apr 1;417:23-34. doi: 10.1016/j.tox.2019.02.008. Epub 2019 Feb 15.
50 P2Y receptor regulation of sodium transport in human mammary epithelial cells. Am J Physiol Cell Physiol. 2007 Nov;293(5):C1472-80. doi: 10.1152/ajpcell.00068.2007. Epub 2007 Aug 22.
51 Influence of cocaine dependence and early life stress on pituitary-adrenal axis responses to CRH and the Trier social stressor. Psychoneuroendocrinology. 2010 Nov;35(10):1492-500. doi: 10.1016/j.psyneuen.2010.05.001. Epub 2010 May 31.
52 Relation of oxytocin to psychological stress responses and hypothalamic-pituitary-adrenocortical axis activity in older women. Psychosom Med. 2006 Mar-Apr;68(2):238-45. doi: 10.1097/01.psy.0000203242.95990.74.
53 Human and murine steroid 5-reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid. Chem Biol Interact. 2019 May 25;305:163-170. doi: 10.1016/j.cbi.2019.03.025. Epub 2019 Mar 28.
54 Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids. Toxicology. 2017 Apr 15;381:51-63.
55 Interferon- is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr Relat Cancer. 2013 May 30;20(3):443-54. doi: 10.1530/ERC-12-0217. Print 2013 Jun.
56 Overexpression of RbAp46 facilitates stress-induced apoptosis and suppresses tumorigenicity of neoplastigenic breast epithelial cells. Int J Cancer. 2003 Jul 20;105(6):762-8. doi: 10.1002/ijc.11148.
57 Stimulation of progesterone, estradiol and cortisol in trophoblast tumor bewo cells by glycodelin A N-glycans. Anticancer Res. 2007 Jul-Aug;27(4A):2101-8.
58 Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. Horm Metab Res. 2011 May;43(5):337-42. doi: 10.1055/s-0031-1271693. Epub 2011 Feb 17.
59 Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene. Pediatrics. 2006 Feb;117(2):e322-7. doi: 10.1542/peds.2005-1973. Epub 2006 Jan 3.
60 Mitochondrial proteomics investigation of a cellular model of impaired dopamine homeostasis, an early step in Parkinson's disease pathogenesis. Mol Biosyst. 2014 Jun;10(6):1332-44.
61 Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience. 2016 Oct 1;333:193-203. doi: 10.1016/j.neuroscience.2016.07.020. Epub 2016 Jul 20.
62 Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Mol Psychiatry. 2011 Sep;16(9):927-37, 881. doi: 10.1038/mp.2011.32. Epub 2011 Apr 19.
63 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
64 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
65 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
66 SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
67 Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
68 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
69 Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
70 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
71 Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
72 Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
73 Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6.
74 Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
75 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
76 Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicol Lett. 2016 Jan 22;243:48-55.
77 Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol. 2001 Feb;59(2):393-402. doi: 10.1124/mol.59.2.393.
78 Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513. doi: 10.1016/j.taap.2021.115513. Epub 2021 Mar 27.
79 The effect of rare human sequence variants on the function of vesicular monoamine transporter 2. Pharmacogenetics. 2004 Sep;14(9):587-94. doi: 10.1097/00008571-200409000-00003.
80 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
81 Effects of dopamine on LC3-II activation as a marker of autophagy in a neuroblastoma cell model. Neurotoxicology. 2009 Jul;30(4):658-65. doi: 10.1016/j.neuro.2009.04.007. Epub 2009 May 4.
82 Inhibition of human glutathione S-transferases by dopamine, alpha-methyldopa and their 5-S-glutathionyl conjugates. Chem Biol Interact. 1994 Jan;90(1):87-99.
83 Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004 Apr;9(4):358-70.
84 Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 2008 Jul;36(7):1322-31.
85 Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci. 2006 Sep;24(5):1366-72. doi: 10.1111/j.1460-9568.2006.04998.x.
86 Mitochondrial UCP5 is neuroprotective by preserving mitochondrial membrane potential, ATP levels, and reducing oxidative stress in MPP+ and dopamine toxicity. Free Radic Biol Med. 2010 Sep 15;49(6):1023-35. doi: 10.1016/j.freeradbiomed.2010.06.017. Epub 2010 Jun 19.
87 Ligand binding and aggregation of pathogenic SOD1. Nat Commun. 2013;4:1758. doi: 10.1038/ncomms2750.
88 Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 1995 Oct;352(4):429-37. doi: 10.1007/BF00172781.
89 Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. Am J Ther. 2008 Jul-Aug;15(4):397-402. doi: 10.1097/MJT.0b013e318160c353.
90 Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet. 2004 Aug 15;13(16):1745-54. doi: 10.1093/hmg/ddh180. Epub 2004 Jun 15.
91 Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med. 2007 Jun 30;39(3):376-84. doi: 10.1038/emm.2007.42.
92 Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
93 Dopamine down-regulation of protein L-isoaspartyl methyltransferase is dependent on reactive oxygen species in SH-SY5Y cells. Neuroscience. 2014 May 16;267:263-76. doi: 10.1016/j.neuroscience.2014.03.001. Epub 2014 Mar 12.
94 Sulfation of environmental estrogen-like chemicals by human cytosolic sulfotransferases. Biochem Biophys Res Commun. 2000 Jan 7;267(1):80-4. doi: 10.1006/bbrc.1999.1935.
95 Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci. 2004 Mar 3;24(9):2212-25. doi: 10.1523/JNEUROSCI.4847-03.2004.
96 Expression of tyrosine hydroxylase increases the resistance of human neuroblastoma cells to oxidative insults. Toxicol Sci. 2010 Jan;113(1):150-7. doi: 10.1093/toxsci/kfp245. Epub 2009 Oct 8.
97 G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem Int. 2004 Oct;45(5):669-76. doi: 10.1016/j.neuint.2004.03.029.
98 Increased arterial pressure in mice with overexpression of the ADHD candidate gene calcyon in forebrain. PLoS One. 2019 Feb 12;14(2):e0211903. doi: 10.1371/journal.pone.0211903. eCollection 2019.
99 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
100 Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006 Mar;28(2):99-103. doi: 10.1016/j.braindev.2005.05.005. Epub 2005 Sep 15.